Recent Experimental and Clinical Findings in the Skeleton Associated with Loss of Estrogen Hormone or Estrogen Receptor Activity by Smith, Eric P. et al.
South Dakota State University
Open PRAIRIE: Open Public Research Access Institutional
Repository and Information Exchange
Ethel Austin Martin Program Publications
2-2010
Recent Experimental and Clinical Findings in the
Skeleton Associated with Loss of Estrogen
Hormone or Estrogen Receptor Activity
Eric P. Smith
University of Cincinnati
Bonny Specker
South Dakota State University, Bonny.Specker@sdstate.edu
Kenneth S Korach
Follow this and additional works at: https://openprairie.sdstate.edu/eam_pubs
Part of the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by Open PRAIRIE: Open Public Research Access Institutional Repository and Information
Exchange. It has been accepted for inclusion in Ethel Austin Martin Program Publications by an authorized administrator of Open PRAIRIE: Open
Public Research Access Institutional Repository and Information Exchange. For more information, please contact michael.biondo@sdstate.edu.
Recommended Citation
Smith, Eric P.; Specker, Bonny; and Korach, Kenneth S, "Recent Experimental and Clinical Findings in the Skeleton Associated with
Loss of Estrogen Hormone or Estrogen Receptor Activity" (2010). Ethel Austin Martin Program Publications. 60.
https://openprairie.sdstate.edu/eam_pubs/60
Recent experimental and clinical findings in the skeleton 
associated with loss of estrogen hormone or estrogen receptor 
activity⋆
Eric P. Smitha,*, Bonny Speckerb, and Kenneth S. Korachc
aDepartment of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, University 
of Cincinnati College of Medicine, Cincinnati, OH 45267, United States
bSouth Dakota State University, Ethel Austin Martin Program in Human Nutrition, Brookings, SD 
57007, United States
cLaboratory of Reproductive and Developmental Toxicology, National Institute of Environmental 
Health Sciences, Research Triangle Park, NC 27709, United States
Abstract
Studies on rodent models and rare human disorders of estrogen production or response have 
revealed an increased complexity of the actions of estrogen on bone. ERα disruption in human 
males results in delayed epiphyseal maturation, tall stature, trabecular thinning, marked cortical 
thinning, genu valgum and significantly reduced cortical vBMD, but trabecular number is 
preserved and there is normal to increased periosteal expansion. Aromatase deficiency results 
overall in a similar phenotype, although less is known about skeletal architecture. Importantly, 
estrogen replacement in these individuals, even if provided late in the third decade, may normalize 
aBMD. Less certain is whether there is complete recovery of normal skeletal architecture and 
strength. Rodent models, in general, are consistent with the human phenotype but are confounded 
by inherent differences between mouse and human physiology and issues regarding the 
completeness of the different knock-out lines. Both human and rodent studies suggest that residual 
effects of estrogen through ERβ, truncated ERα forms or nonclassical estrogen receptors might 
account for different phenotypes in the hERKO man, aromatase deficient subjects and rodents. 
Importantly, androgen, particularly by preserving trabecular number and augmenting both 
periosteal and epiphyseal growth, also has significant actions on bone.
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1. Introduction
Estrogen is well known to be important in females for bone growth and metabolism. 
However, evidence has emerged from rodent models [1] and rare disorders of estrogen 
production or response in humans [2,3] that the physiologic role for estrogen is far more 
complicated, involving actions in males as well as females [4]. Estrogen actions are further 
complicated by the presence of two distinct but related nuclear receptors, ERα [4] and ERβ 
[5], both with different splice variants [6] and the recent discovery of a membrane bound 
functional ER, the G protein-coupled receptor GPR30 [7–9]. For this review, we will 
describe recent experimental evidence from human and animal models that increase 
understanding of the role of estrogen relative to androgen in bone.
2. Production and cellular mechanism of action of estrogen
Circulating estrogens are produced from the aromatization of androgens by the cytochrome 
P450 enzyme, aromatase [10]. In males, unlike females in which the ovaries are the primary 
source of estrogen, the majority of the estrogen in the circulation is derived from 
extragonadal tissues [11]. The regulation of aromatase activity in different tissues such as 
breast, adipose and gonads is complex and it is increasingly clear that in addition to classical 
hormonal pathways there are important local regulatory mechanisms in place that regulate 
estrogen production in a tissue specific manner [12–14]. Estrogen produced by androgen 
aromatization induces cellular changes by several different mechanisms [15]. The major 
signal transducers are two distinct receptor proteins, ERα and ERβ, which have distinct 
tissue expression patterns [16] in both humans and rodents. ERα and ERβ are encoded by 
unique genes from separate chromosomal locations. Estrogens are thought to diffuse into 
target cells and are bound by the ER, which is located primarily in the nucleus, but can also 
be associated with the plasma membrane [17]. Recently, the membrane form [18] has been 
demonstrated to be unable to rescue a deficiency in the nuclear located receptor. The nuclear 
ER-estrogen complex can regulate genes, positively or negatively, by binding directly to 
specific DNA sequences in the promoter region of regulated genes involving the recruitment 
of coregulatory proteins (coactivators or corepressors) to the promoter, producing increased 
or decreased mRNA levels and associated protein production, and resulting physiological 
response. Gene-targeted knock-out mouse models lacking these receptors exhibit distinct 
phenotypes [19].
An alternative mode of action of estrogen involves an indirect mechanism by which the ER 
does not bind directly to the DNA but interacts with existing transcription factors; this is 
referred to as the tethered mechanism of nuclear receptor gene regulation [20,21]. To elicit 
many actions of the hormone this “genomic” mechanism typically occurs over the course of 
hours in most tissues. In contrast, non-genomic mechanisms, can also occur with estrogen, 
either through the ER located in or adjacent to the plasma membrane involving adaptor 
proteins such as caveolin-1 or Shc, or through other non-ER plasma membrane–associated 
estrogen-binding proteins, such as GPR30 [22], resulting in cellular responses such as 
activation of kinases which then acts to prime the genomic actions. Finally, a third aspect of 
ER activity involves the ligand independent activation of the receptor protein. Such an 
action has been shown experimentally in cells and animal models, involving the activation 
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of kinase cascades by growth factors or other membrane signaling agents [23]. The extent to 
which any of these specific mechanisms are involved in mediating the physiological actions 
of estrogen still requires considerable study in order to develop effective biomedical 
understanding and therapeutic treatment.
3. Control of longitudinal growth and final stature
The most visible action of estrogen on the human skeleton for both males and females is 
control of body proportion and determination of final stature [2,3]. The male identified with 
ERα point mutation (hERKO), described throughout this review, is a unique individual and 
clinical case. He presented at age 28 with tall stature (204 cm), eunuchoid body proportions 
(0.83 (average for men, 0.96)), unfused epiphyses (bone age ~15 years) and moderate to 
severe genu valgum. Unlike normal males, in which there is a self-limited surge of estrogen 
coinciding with a growth spurt [24], in the hERKO man there was likely a prolonged phase 
of elevated estrogens associated with sustained linear growth into his third decade. There 
was a minimal bone age progression despite normal testosterone and insulin-like growth 
factor-I (IGF-I) levels. Tall stature ensued but with marked eunuchoid body proportions and 
debilitating genu valgum. This is strikingly similar to reports in 7 aromatase deficient (AD) 
men all whom presented either in their 3rd or 4th decade with tall stature ranging from 183 
to 204 cm, bone ages ranging from 14.5 to 16.5 years, genu valgum and eunuchoid body 
proportions (see Table 1) [2,25–31]. By contrast, a 8th case of aromatase deficiency 
presented at age 17.1 years with a bone age of 12, normal stature and apparently normal 
body proportions [32] and an 9th case was reported as a male infant [33]. Importantly, in the 
aromatase deficient cases in which estrogen treatment was initiated [30,34–37], there was 
epiphyseal maturation, but only in the adolescent-aged individual was a significant growth 
acceleration observed [32]. AD has been reported in 11 females to date [2] but are readily 
identified early in life secondary to virilization; estrogen therapy is instituted before a bone 
phenotype becomes manifest.
Consistent with the longitudinal growth observations, ERα and ERβ [38–42], and more 
recently with the GPR30 [22,43], a G protein membrane estrogen signaling receptor, have 
been localized to human growth plate chondrocytes. In the rabbit, which resembles the 
human with respect to epiphyseal fusion in response to estrogen, ERα is readily detectable 
in resting, proliferative and hypertrophic chondrocytes [44]. However, animal models other 
than the rabbit and human have manifested different phenotypes, perhaps in part because of 
fundamental differences in growth dynamics [45–49]. Notably, in normal mice, the 
epiphyses do not completely fuse during the equivalence of puberty [24,50,51]. Further 
complicating interpretation is a sexually dimorphic age dependent pattern in the mouse 
knock-out models [52] and differences related to the degree of completeness of the knock-
out [1,21,53,54]. For example, putatively complete ERKO mice [55] appear to have femur 
bone length similar to wild type in both males and females, while other reports indicate 
shorter bones in both males and females [56,57]. ERβknock-out (bERKO) male and young 
and old female mice display unchanged femur lengths whereas in intermediate aged female 
mice with naturally occurring high estrogen levels have longer bones [49]. However, 
bERKO female mice do not have abnormal estrogen levels compared to wild type 
[55,58,59]. Aromatase deficient mice (ArKO) phenotype reveals a shortened femur length in 
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males with less effect in females [45,46]. GRP30 knock-out female mice are smaller than 
normal where as male knock-out animals appear similar to wild type controls [60]; 
subsequent analysis of the effect of ovariectomy on female GRP30−/− animals reveals 
decreased femur length compared to wild type ovariectomized with reduced impact of 
estrogen replacement [61]. Finally, androgen receptor knock-out (ARKO) mouse models 
show shorter femurs accompanied by osteopenia only in males and not in females [62].
As a result of the disparate phenotypes, the primary reason for difference in phenotypes 
between rodents and man remains largely speculative. Does ERβ account for some estrogen-
mediated actions on epiphyseal maturation? Do the shorter femurs in female GRP30−/− 
animals coupled with localization of GRP30 in growth plates indicate an important function 
for GRP30 mediated estrogen signaling in bone growth? If so, why only in female mice and 
why are femurs shorter rather than longer? An intriguing potential explanation has been 
suggested from the observation that hERKO man possessed a mutation in exon 2 consisting 
of a cytosine-to-thymine transition at codon 157 of both alleles, resulting in a premature stop 
codon that likely produced a truncated protein [3,52,53]. There is in vitro evidence that this 
truncated product may sustain some residual estrogenic activity [52,63]. Chagin and 
Savendahl [52] have speculated that this residual truncated N-terminal fragment [6,52,53,64] 
in the hERKO man may have served to retard epiphyseal closure until the 4th decade of life 
by acting as a dominant negative inhibitor of ERβ. However, no experimental studies have 
indicated such a mechanism to date. In fact, cultured bone cells from the ERKO man, 
despite having both ERβ mRNA and protein, failed to elicit any estrogen responsiveness 
relative to control wild type cells [65,66]. The fused epiphyses ultimately occurred in the 
hERKO man at age 35.5 without the benefit of significant estrogen intervention [65] but 
with elevated endogenously produced estrogen. Epihyseal fusion could be explained by a 
prolonged action of modestly high estrogens through either ERβ, GRP30 or truncated ERα 
but there remains no definitive evidence for any of these possibilities.
Although the ArKO cases and hERKO man clearly demonstrate that estrogen is critical for 
final epiphyseal maturation, a closer examination of their “pubertal” increment in growth 
does not implicate conclusively which sex steroid, androgen or estrogen, in addition to the 
prerequisite contribution of other hormone systems such as the GH-IGF-I axis [67–69], is 
the primary mediator of the pubertal growth spurt that is typically about 15–20% of final 
height [67,70,71]. Bone ages in the hERKO man and male aromatase deficient patients at 
presentation were substantially more advanced though not fused, and stature was greater, 
than in late presenting hypogonadal individuals [72,73]. Interestingly, the available 
longitudinal growth data in the hERKO case and the aromatase deficient patients suggest 
that a pubertal growth spurt occurred since the documented statures at age 18 matched the 
predicted height based on parental target range. This was followed during the third decade 
by tall stature greater than observed in isolated hypogonadism [69,74], eunuchoid body 
proportions similar to isolated hypogonadism and genu valgum seemingly more severe than 
reported with hypogonadism [72–74]. Although androgen insensitivity (AI) syndromes 
argue strongly that estrogen in the absence of a functional androgen receptor (AR) can 
induce both a growth spurt and epiphyseal maturation [75–77], there is controversy in these 
rare individuals regarding whether estrogen can fully compensate for the lack of androgen 
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action [75,78]. Do the available data support the notion that androgen can promote growth 
without inordinate bone age maturation under some circumstances? The growth data of 
hypogonadal individuals, particularly with intact adrenal androgen levels and normal growth 
hormone secretion [72,73], reveal an apparent maintenance of prepubertal height velocity 
during the first half of the second decade. Bone age is delayed but a full growth increment 
characteristic of puberty does not generally occur. This suggests that the differences in the 
growth observed in the hERKO case and the aromatase deficiency patients compared with 
hypogonadal individuals is related to combined androgen exposure and effectively deficient 
estrogen state. Seemingly, despite the well-documented actions of nonaromatizable 
androgen to advance bone age [79–82], under some circumstances androgen levels in the 
pubertal range can promote pubertal growth without rapid maturation of the epiphyses in the 
absence of full estrogen action.
What precise sex steroid environment promotes linear growth without inordinately 
advancing bone age is an important question to address in future clinical studies. Modulation 
of estrogen exposure, while simultaneously maintaining normal circulating androgens, has a 
number of intriguing potential benefits. Age-appropriate masculinization can be achieved 
while suppressing bone age maturation. In addition, maintenance of androgen concentrations 
allows for greater increments in height per unit of bone age advancement and, as mentioned 
later in this review, may result in simultaneous periosteal growth of the skeleton and could 
lead to a greater peak bone mass. As already indicated, this is a markedly different outcome 
from the tapered height velocity observed in longstanding hypogonadism [24] and may 
result in a larger and stronger skeleton less susceptible to fractures.
A tentative overall conclusion is that normal to increased stature can ultimately evolve over 
time without estrogen and that bone age maturation tends to arrest at about 15 years. Final 
epiphyseal fusion, coupled with a growth spurt, is, however, observed only if estrogen 
exposure occurs at younger bone ages. This conclusion suggests that manipulation of 
estrogen production and/or signaling has potential for augmenting final height. Recent 
studies using aromatase inhibitors confirm the potential for increasing stature in a variety of 
clinical conditions by modulating estrogen concentrations [83]. For example, Mauras et al. 
[84], in a study involving 52 short adolescent males randomized to receive either anastrozole 
or placebo for up to 36 months, demonstrated similar linear growth with a decrease in the 
rate of bone age advancement. The resulting increase in predicted height at 36 months was 
+6.7 ± 1.4 cm for the anastrozole group. Importantly, there was no significant difference in 
the spine BMD Z-score. However, the authors and a recent position statement by the 
Lawson Wilkins Pediatric Endocrine Society [85] stress that long-term follow-up is needed 
before aromatase inhibitors are used in children for stature manipulation outside of a 
controlled trial setting.
A final important caveat, however, to the prospects for sex steroid manipulation of final 
height is that there are senescence factors, intrinsic to the epiphysis, that serve to define an 
overall limit on final stature [24]. The near final epiphyseal fusion in the hERKO subject in 
particular supports this notion. Not only was linear growth without ERα activity largely 
completed by the middle to end of the 3rd decade in this patient and in the aromatase 
deficient cases, but the increased stature was accompanied by abnormalities of the body 
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proportion, marked genu valgum, and osteopenia. The role of estrogen appears to be 
accelerate senescence within a growth plate that has an internal program limiting the number 
of chondrocyte divisions [24,86]. Though both high doses of estrogen and early estrogen 
exposure will reduce final height [87], estrogen exposure within the physiologic range is not 
associated with significantly compromised final height and reduced estrogen production in 
boys with constitutional delay may lead to improved height prediction. The rapid fusion 
observed in the estrogen treated aromatase patients [26] and the progressive epiphyseal 
maturation observed in young children with precocious puberty [88] all point to a program 
of senescence within the growth plate that estrogen is able to modulate in humans and in 
some mammals. Stature increments, substantially beyond the normal genetic potential, are 
not likely to be achieved safely by manipulating estrogen action for more than a few years.
4. Bone mineral density and architectural integrity in human models
The next most consistent clinical phenotype of human models of estrogen deficiency and/or 
resistance is marked decreased areal measures of bone mineral density (aBMD). The 
decreased spine aBMD in the 7 reported aromatase patients improved significantly within 6 
months of estrogen treatment (Table 1). The decreased aBMD is presumably a manifestation 
of decreased trabecular volume from increased bone resorption coupled with decreased bone 
formation, a predictable outcome of the severe disruption in estrogen action [89,90] on 
trabeculae, a well-documented site for ERα [38,40] and ERβ [38,40] receptor expression in 
both osteoblasts and osteoclasts. Interestingly, many studies on the relationship between 
bone and circulating sex steroids in men suggest a greater correlation with estradiol than 
testosterone [91–94]. However, with the hERKO man, the only case with a detailed 
histomorphometric analysis [65], preservation of trabecular number is documented. This is 
not characteristic of male and female hypogonadism, and is more typical of the aging 
skeleton with normal androgen concentrations [95]. The preserved trabecular number may 
be explained, in part, by residual actions of estrogen through ERβ [55], known to be 
expressed in human osteoblasts [38] and osteoclasts [39,40], and normal androgen levels 
[96,97]. Studies involving supplementation with testosterone [98] to standard estrogen/
progesterone replacement in postmenopausal women and analysis of AI individuals [75] 
strongly suggest important actions of androgens on trabecular bone. Androgen receptors 
have been reported in human osteoblasts [99,100]. Finally, in the detailed longitudinal 
follow-up of the aromatase subject described by Rochira et al. [36]; following a window of 
estrogen replacement for approximately 2 years, androgen was added to the regimen with a 
further increase in spine aBMD from 1.018 g/cm2 to 1.134 g/cm2. The authors’ 
interpretation is that the full anabolic action of estrogen requires androgen. Regardless, a 
potential clinical implication is that interventions that augment ERα pathways and preserve 
the anabolic actions of androgen may be particularly effective in maintaining and/or 
augmenting trabecular bone.
It is interesting to compare these observations with the impact of estrogen on human bone 
among lactating women. Decreases of 3–9% in spine and femoral neck aBMD have been 
reported among lactating women [101–103]. This decrease occurs rapidly within the first 3–
6 months of lactation, reaching rates of bone loss of 1% per month. However, the amount of 
bone lost during lactation is variable and the length of postpartum amenorrhea is an 
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important determinant. Although the length of postpartum amenorrhea is associated with the 
length of lactation, some women resume menses while still breastfeeding. Several studies 
have found that the net change in spine aBMD is less in women who resumed menses during 
lactation compared to women who do not resume menses [103,104]. Importantly and 
particularly relevant for this review, spine aBMD increases on average 5.2% between 6 and 
12 months postpartum, the majority of this increase occurring following weaning [103] and 
women with high parity who breast-fed their children have greater bone cross-sectional area 
and bone bending strength later in life [105]. These findings underscore the importance of 
estrogen in regulating bone loss during lactation and suggest there are inherent mechanisms 
for skeletal recovery from periods of lowered estrogen.
Another remarkable set of findings observed in 2 of the aromatase patients by pQCT and by 
both pQCT and histomorphometry in the hERKO males is a marked thinning of the cortex 
with low cortical vBMD and increased trabecularization by histomorphometry [65] (Table 
2). The decreased cortical thickness was present with normal to increased periosteal 
circumference or cross-sectional bone area (Fig. 1). The ArKO subject described by 
Rochira, who was also hypogonadal with low testosterone concentrations, showed increases 
in cortical thickness and periosteal expansion with testosterone plus estrogen replacement 
[36]. Bone cross-sectional area is greater in men and is considered to be secondary to the 
increased periosteal apposition rate induced by androgens [106–109] and a possible 
inhibition of resorption on endosteal surfaces by estrogen [110]. Postmenopausal women are 
susceptible to increased endosteal bone loss relative to men, exhibit less periosteal 
apposition of new bone, and display greater cortical porosity [111].
The greater cortical vBMD that is observed in women of reproductive age has been 
hypothesized to be a result of estrogen-driven packing of excess bone for needs related to 
pregnancy and lactation [112]. Although estrogen is considered by some to exert primarily 
inhibitory actions on periosteal expansion, there is recent evidence from animals models that 
many of the actions of estrogen on periosteum may be to stimulate expansion through ERα, 
but in a dosage sensitive manner, and potentially, in collaboration with androgen actions 
[76,76,97,113,114] on periosteally located AR [114]. However, recent studies have found 
that estrogen does not have an independent effect on periosteal expansion and that the action 
of estrogen and bone loading on bone structure are independent and additive [115]. In the 
aromatase deficient subject presenting at age 17 years described by Bouillon et al., estrogen 
replacement alone appeared to induce modest linear growth but skeletal size was 
proportionately augmented; total vBMD and bone mineral apparent density (BMD adjusting 
for bone size) at the 4% distal radius measured by pQCT were unchanged, yet aBMD at the 
same location was increased, indicating that bone size and not true volumetric density were 
affected [32]. However, longitudinal measures at the 4% distal radius are difficult to 
compare due to large differences in bone diameter that occur at this location within very 
short distances. Because of the continued growth of this individual, it would have been 
impossible to measure the same location repeatedly over time, making the results difficult to 
interpret.
Related to the above description of the periosteum, bone width is affected in both the 
hERKO and aromatase deficient subjects. Specifically, wrist breadth at time of presentation 
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of the hERKO man was greater than normal at 7.2 cm (normal adult males: 6.0 ± 0.5 [mean 
± SD]; normal adult females: 5.3 ± 0.3 cm) and the width of the distal femurs were both 
estimated to be 113 mm (normal adult male 90 ± 7 mm). The skeletal “frame size” as 
measured at the wrist and knee is distinctly different from the ectomorphic appearing 
skeleton of longstanding hypogonadism [116] and this phenotype may be due to important 
actions of androgen in these individuals [79,97,113]. The ArKO subjects have normal to 
slightly elevated androgen prior to intervention and this may serve to maintain and/or 
augment bone size. In the ArKO patient described by Bouillon et al. [32], the initiation of 
estrogen replacement, which was followed by reduction but relative maintenance androgen 
concentrations, resulted in significant increase in skeletal size based on the observation that 
despite increases in cortical cross-sectional area, vBMD remained unchanged [32]. This 
notion that androgen enlarges the skeleton is supported by studies demonstrating that 
femoral area of androgen resistant rats is lower compared to normal males [117]. In 
addition, it is well established that androgen stimulates periosteal bone growth [79,118–120] 
and different skeletal domains such as the mandible [121,122] display sexual dimorphism.
5. Conclusions
Detailed analysis of homozygous-affected hERKO patient and aromatase individuals, as 
well as appropriate experimental animal models, suggest a complex contribution of estrogen 
to bone growth, aBMD, and skeletal structural integrity (Fig. 2). ERα disruption specifically 
results in delayed epiphyseal maturation, tall stature, trabecular thinning, marked cortical 
thinning, significantly reduced cortical vBMD, and normal to increased periosteal 
expansion. Of significant clinical relevance, debilitating genu valgum evolves. This supports 
an important role for ERα in mediating the actions of estrogen on the male skeleton, a result 
supported from the animal models as well. Whether this would hold true for female subjects 
is not known at the current time, since no hERKO female patients have been identified and 
the findings in the female mice are not as revealing as expected. Lack of estrogen due to 
aromatase deficiency results in a similar phenotype though less is known about skeletal 
architecture. Estrogen replacement, even if provided late in third decade may normalize 
aBMD, although it is less clear if there is complete recovery of normal skeletal architecture 
and strength. It also is not clear whether the residual effect of estrogen through ERβ, 
truncated ERα or GPR30 might manifest a different phenotype in the hERKO man than 
aromatase deficient subjects. Androgen, particularly by preserving trabecular number and 
augmenting both periosteal and epiphyseal growth, has important actions on bone. Targeting 
both ER and AR and the production of their respective activating hormones and/or mimetics 
will provide complimentary strategies to the management of sex hormone-regulated diseases 
such as osteoporosis and short stature.
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Fig. 1. 
pQCT images of hERKO subject and normal man. This figure depicts pQCT images at the 
4% (left) and 20% (right) distal radius in the hERKO subject (top row, A) and a man with 
similar arm length (bottom row, B). Decreased cortical thickness is apparent at both sites, as 
well as increased periosteal circumference and decreased trabecular vBMD, at the 4% distal 
radius.
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Fig. 2. 
Summary of the action of estrogen and androgen on bone. This figure depicts a rendition of 
a human distal femur. The principle actions of the sex steroids on bone are demonstrated 
based on the clinical findings in ArKO male subjects and the hERKO man. The action of 
androgen are listed on the left; the effects of estrogen on the right. The combined actions are 
shown on the lower middle.
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